BV and beyond: how to incorporate novel agents into PTCL management

Keyphrases

• Novel Agents 100%
• Peripheral T-cell Lymphoma 100%
• Histone Deacetylase Inhibitor (HDACi) 40%
• CD30 40%
• Brentuximab Vedotin 40%
• Frontline Treatment 40%
• EZH2 Inhibitor 40%
• Follicular T-cell Lymphoma 40%
• Natural Killer Cells 20%
• Duvelisib 20%
• Relapsed or Refractory 20%
• T Cells 20%
• Recent Advances 20%
• Lymphoma 20%
• Treatment Regimen 20%
• Patient-specific Therapy 20%
• Targeted Agents 20%
• Antibody-drug Conjugate 20%
• Relapsed Disease 20%
• Subtype-specific 20%
• Anaplastic Large Cell Lymphoma 20%
• Epigenetic Regulators 20%
• Cell Precursors 20%
• Regulatory Genes 20%
• Extranodal Lymphoma 20%
• Hypomethylating Agents 20%
• Ongoing Trials 20%
• Frequent mutation 20%
• Ruxolitinib 20%
• Azacitidine 20%
• Inhibitor Agent 20%

Medicine and Dentistry

• Peripheral T-Cell Lymphoma 100%
• Histone Deacetylase Inhibitor 33%
• T-Cell Lymphoma 33%
• Brentuximab Vedotin 33%
• T Follicular Helper Cell 33%
• Diseases 33%
• Natural Killer Cell 16%
• Duvelisib 16%
• Precursor 16%
• Regulator Gene 16%
• T Cell 16%
• Antibody-Drug Conjugate 16%
• Anaplastic Large Cell Lymphoma 16%
• Hypomethylating Agent 16%
• Ruxolitinib 16%
• Azacitidine 16%